Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis

IF 4.6 2区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

iScience Pub Date : 2024-11-07 DOI:10.1016/j.isci.2024.111343

Xin Zhang , Licheng Wei , Jiangguo Li , Yuexia Deng , Wei Xu , Dongkui Chen , Xing Li

{"title":"Influence of myosteatosis on survival of patients with pancreatic cancer: A systematic review and meta-analysis","authors":"Xin Zhang , Licheng Wei , Jiangguo Li , Yuexia Deng , Wei Xu , Dongkui Chen , Xing Li","doi":"10.1016/j.isci.2024.111343","DOIUrl":null,"url":null,"abstract":"<div><div>The present meta-analysis aims to evaluate the impact of myosteatosis on overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer (PC). A comprehensive literature search was conducted in the Medline, Web of Science, and Embase databases. The hazard ratio (HR) and corresponding 95% confidence interval (CI) for the association between myosteatosis and survival outcomes were pooled using a random-effects model. A total of 14 studies were included. The pooled analysis demonstrated that myosteatosis was significantly associated to poorer OS (HR: 1.50, 95% CI: 1.35–1.67, <em>p</em> < 0.001; <em>I</em><sup><em>2</em></sup> = 0%). The subgroup analysis revealed consistent results across various study characteristics, including geographic regions, cancer stages, follow-up durations, and study quality. In addition, myosteatosis was associated to worse PFS (HR: 1.34, 95% CI: 1.15–1.57, <em>p</em> < 0.001; <em>I</em><sup><em>2</em></sup> = 34%). The present meta-analysis indicates that myosteatosis is associated to significantly worse OS and PFS in patients with PC.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"27 12","pages":"Article 111343"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004224025689","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

The present meta-analysis aims to evaluate the impact of myosteatosis on overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer (PC). A comprehensive literature search was conducted in the Medline, Web of Science, and Embase databases. The hazard ratio (HR) and corresponding 95% confidence interval (CI) for the association between myosteatosis and survival outcomes were pooled using a random-effects model. A total of 14 studies were included. The pooled analysis demonstrated that myosteatosis was significantly associated to poorer OS (HR: 1.50, 95% CI: 1.35–1.67, p < 0.001; I² = 0%). The subgroup analysis revealed consistent results across various study characteristics, including geographic regions, cancer stages, follow-up durations, and study quality. In addition, myosteatosis was associated to worse PFS (HR: 1.34, 95% CI: 1.15–1.57, p < 0.001; I² = 34%). The present meta-analysis indicates that myosteatosis is associated to significantly worse OS and PFS in patients with PC.

Abstract Image

查看原文本刊更多论文

肌骨质疏松症对胰腺癌患者生存期的影响：系统回顾与荟萃分析

本荟萃分析旨在评估肌骨肥大症对胰腺癌（PC）患者总生存期（OS）和无进展生存期（PFS）的影响。我们在 Medline、Web of Science 和 Embase 数据库中进行了全面的文献检索。采用随机效应模型对肌骨营养不良与生存结果之间关系的危险比（HR）和相应的 95% 置信区间（CI）进行了汇总。共纳入 14 项研究。汇总分析表明，肌骨营养不良与较差的OS显著相关（HR：1.50，95% CI：1.35-1.67，p < 0.001；I2 = 0%）。亚组分析显示，不同研究特征的结果一致，包括地理区域、癌症分期、随访时间和研究质量。此外，肌骨质疏松症与较差的 PFS 相关（HR：1.34，95% CI：1.15-1.57，p <；0.001；I2 = 34%）。本荟萃分析表明，肌骨肥大症与PC患者的OS和PFS显著恶化有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iScience Multidisciplinary-Multidisciplinary

CiteScore

7.20

自引率

1.70%

发文量

1972

审稿时长

6 weeks

期刊介绍： Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.